MFN2 and diabetic kidney disease: There are also some limitations to our results and list as follows: 1) Renal biopsies from patients with DKD according to DKD staging could further analyze the role of Mfn2 in the development of DKD; 2) Lack of a podocyte-specific Mfn2 knockout animal model to directly observe the effect of Mfn2 deletion on PERK pathway-related alterations in podocytes; 3) Lack of functional testing of MAMs such as Ca2+ signal transmission to provide a more complete theoretical basis for our conclusion.